Blockchain Registration Transaction Record

Oragenics Partners with DUCK FLATS Pharma to Advance Intranasal Concussion Therapy

Oragenics partners with DUCK FLATS Pharma to advance ONP-002, an intranasal concussion therapy, through FDA preparation and clinical trials. Learn about this innovative neurological treatment development.

This development matters because concussions and mild traumatic brain injuries represent a significant public health concern affecting millions annually, from athletes to accident victims, with limited treatment options currently available. Oragenics' ONP-002, as a potential first-in-class intranasal therapy, could revolutionize concussion treatment by offering targeted brain delivery that may improve recovery outcomes and reduce long-term neurological complications. The partnership with DUCK FLATS Pharma accelerates the path toward FDA approval, potentially bringing this innovative treatment to patients sooner. Successful development could also validate Oragenics' intranasal platform for other neurological conditions like Parkinson's and Alzheimer's, addressing broader unmet medical needs in neurology.